Poseida Therapeutics, Inc.

Total Valuation

Poseida Therapeutics, Inc. carries a market capitalization of 925.93M, placing it among publicly traded companies globally. Its enterprise value stands at 128.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Poseida Therapeutics, Inc. currently has 97.41M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 1.83, and the price-to-book ratio stands at -0.44.

Enterprise Valuation

Financial Position

Poseida Therapeutics, Inc. maintains a current ratio of 3.20, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 94.86, indicating elevated leverage, while an interest coverage ratio of -6.28 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Poseida Therapeutics, Inc. has paid 43,000.00 in income taxes, reflecting an effective tax rate of 0.21.

Stock Price Statistics

Poseida Therapeutics, Inc.'s stock has gained approximately 150.65963% over the past 52 weeks. The 50-day moving average sits at 6.66, while the 200-day moving average is 3.82.

Income Statement

Over the trailing twelve months, Poseida Therapeutics, Inc. generated 150.86M in revenue and converted that into -60.76M in net income, yielding earnings per share of -0.63. EBITDA reached -57.01M, while operating income came in at -62.50M.

Balance Sheet

Poseida Therapeutics, Inc. holds 230.85M in cash and equivalents against 82.73M in total debt, resulting in a net debt position of 9.57M. Total book value stands at -629.69M, with working capital of 172.44M providing operational flexibility.

Cash Flow

Poseida Therapeutics, Inc. produced -15.02M in operating cash flow over the past twelve months. After subtracting -2.10M in capital expenditures, free cash flow totaled -17.13M - equivalent to -0.18 per share.

Margins

Poseida Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -41.43 and net profit margin of -40.28 provide insight into operational efficiency.

Dividends & Yields

Scores

Poseida Therapeutics, Inc. posts an Altman Z-Score of -1.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.